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Abstract
Background: Porcine reproductive and respiratory syndrome virus (PRRSV) has been acknowledged as one of the
most important agents affecting swine. The scavenger receptor CD163 is one of the important entry mediators for
PRRSV.
Results: The tD4 and tD5 CD163 genes were amplified, and the PCR products were cloned into pET-28a(+)
(designated pET-28a-tD4 and pET-28a-tD5, respectively). The plasmids pET-28a-tD4 and pET-28a-tD5 were then
transformed into the E. coli BL21 (DE3) strain and expressed by adding 1 mmol/L of isopropyl-beta-D-
thiogalactopyranoside. The proteins were highly expressed in the supernatant from the tD4- and tD5-producing
cells that were incubated with a binding buffer containing the following compounds: b-mercaptoethanol, urea,
Tween 20, glycerol, and SDS, while they were rarely expressed in the supernatant from the tD4- and tD5-producing
cells that were incubated with binding buffer without the compounds. The tD4 and tD5 proteins were purified,
and BALB/c mice were immunized with the purified proteins. Western blotting analysis showed that the tD4 and
tD5 proteins were capable of reacting with tD5 antibodies; the titer of both the tD4 and tD5 antiserums was 1:160
against the tD5 protein, as shown by ELISA.
Conclusions: These studies provide a new way for the purification of proteins expressed in inclusion bodies and
the preparation of the corresponding antibodies.
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Background
P o r c i n er e p r o d u c t i v ea n dr e s p i r a t o r ys y n d r o m e( P R R S )
has been one of the most important threats to the swine
industry since it was first identified in the United States
in 1987 [1], then in Europe in 1990 [2], and later in
China in 1995 [3]. The clinical manifestations of PRRS
are severe reproductive failure in sows, which includes
early farrowing with stillborn piglets and late-term abor-
tion, respiratory distress in piglets and growing pigs, as
well as an influenza-like disease in grow-finish swine.
Since 2006, a highly pathogenic PRRS virus (PRRSV),
which is characterized by high fever and a high
proportion of deaths in pigs of all ages, has emerged in
some swine farms in China [4,5].
Several cellular factors involved in PRRSV binding and
internalization have been studied, including sialoadhesin
[6,7], heparinlike [8,9], vimentin [10], scavenger receptor
CD163 [11,12], and nonmuscle myosin heavy chain II-A
[13]. CD163, an extracellular protein, consists of a signal
peptide, 9 scavenger receptor cysteine-rich (SRCR) tan-
dem repeats numbered 1-9, a transmembrane (TM)
region, and an intracellular cytoplasmic tail (Figure 1a).
In order to understand the function of SRCRs in CD163,
the prokaryotic expression, purification, and antibody
preparation of the fragment of the extracellular domain
of the receptor CD163 were performed. * Correspondence: guihongzh@scau.edu.cn
† Contributed equally
Key laboratory of Animal Disease Control and Prevention, Ministry of
Agriculture, College of Veterinary Medicine, South China Agricultural
University, Guangzhou 510642, China
Cao et al. Virology Journal 2011, 8:144
http://www.virologyj.com/content/8/1/144
© 2011 Cao et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Materials and methods
Strains, vectors, and main reagents
In this study, we used the E. coli strains DH5a and
BL21(DE3), the expression vector pET-28a(+), and the
plasmids pcDNA3.1-CD163-D4 and pcDNA3.1-CD163-
D5, which were preserved in the author’s laboratory.
Platinum pfx DNA polymerase was purchased from
Invitrogen. Restriction enzymes, DNA markers, and iso-
propyl-beta-D-thiogalactopyranoside (IPTG) were pur-
chased from TaKaRa. T4 DNA Ligase and protein
molecular weight markers were purchased from Fer-
mentas. Plasmid Mini Kits and Gel Extraction Kits were
p u r c h a s e df r o mO M E G A .N iS e p h a r o s6F a s tF l o ww a s
purchased from GE Healthcare.
PCR amplification of the CD163 tD4 and CD163 tD5
genes
Based on the CD163 sequence, the primers for the amplifi-
cation of the CD163 tD4 and CD163 tD5 genes were
designed using the biological software Oligo v. 6.0 and
synthesized by Invitrogen (Figure 1). The forward primer
was 5’-TATGAAGCTTgcATGAGCAAACTCAGAAT
GGTG-3’ and the reverse primer was 5’-TGTACTC-
GAGTGTGGCTTTTTGTGGGG-3’, and these primers
contained the Hind III and Xho I restriction sites (under-
lined), respectively.
Using the plasmids pcDNA3.1-CD163-D4 and
pcDNA3.1-CD163-D5 as the templates, PCR reactions
(100 μL/tube) were performed using 10 μL of 10× pfx
buffer, 8 μLo fd N T Pm i x( 1 0m M ) ,2μLo fM g S O 4
(50 mM), 2 μL of Platinum pfx DNA polymerase, 2 μL
of each primer (10 μM), 1 μL of DNA template, and
73 μL of ultrapure water. The conditions of the PCR
amplification were initial denaturation at 94°C for
3 min, followed by 30 consecutive cycles of denaturation
at 94°C for 30 s, annealing at 55°C for 30 s, and exten-
sion at 68°C for 105 s, and then a final extension at
68°C for 7 min. The amplifiedp r o d u c t sw e r ea n a l y z e d
by electrophoresis on a 1% (w/v) agarose gel.
Construction of the expression plasmids pET-28a-tD4 and
pET-28a-tD5
The PCR products of the CD163 tD4 and CD163 tD5
genes were digested by Hind III and Xho Ia n dd i r e c -
tionally ligated into the previously Hind III/Xho I-
digested expression vector, pET-28a(+). The ligation
mixture was transformed into competent E. coli DH5a
cells for storage. The positive colony was identified by
restriction analysis and sequencing analysis. The
extracted positive plasmids were transformed into the
competent E. coli strain BL21(DE3).
Protein expression, purification, and polyclonal antibody
production
The pET-28a-tD4 and pET-28a-tD5 positive cloning
strains were each inoculated into 5 mL of LB/Kan liquid
medium and cultivated overnight. The 50 μLc u l t u r e s
were inoculated with 5 mL of LB/Kan for activation.
When the bacterium reached the logarithmic phase (at
OD600 of 0.5-0.6), IPTG (final concentration 1.0 mmol/
L) was added in order to induce the expression of the
tD4 and tD5 proteins. The level of protein expression
was analyzed by SDS-PAGE. The uninduced and vector
control cultures were analyzed in parallel. In order to
increase the production of the recombinant proteins, the
expression conditions, including the duration of induc-
tion, the concentrations of IPTG, and the composition
of the binding buffer (Formula of binding buffer with
compounds: 20 mM Na3PO4, 0.5 M NaCl, 20 mM imi-
dazole, 0.5% b-mercaptoethanol, 1.3 M urea, 0.5%
Tween 20, 3% glycerol, 1% SDS, pH 7.4; Formula of
binding buffer without compounds: 20 mM Na3PO4,
0.5 M NaCl, 20 mM imidazole, pH 7.4.) were optimized.
The tD4 and tD5 proteins were purified by Ni
Sepharos 6 Fast Flow. The samples from the Ni-column
were assessed by SDS-PAGE. The purified proteins were
Figure 1 CD163 deletion constructs were used to prepare a
polyclonal antibody of the fragment of the extracellular
domain. (a) The structural domain organization of CD163 consists
of 9 extracellular scavenger receptor cysteine-rich (SRCR) domains, 2
proline-serine-threonine (PST)-rich domains, a transmembrane
region (TM domain), and a cytoplasmic tail. (b) The domain
organization of the CD163 deletion mutants: For the tD4 mutant,
the first 4 SRCR domains, the TM domain, and the cytoplasmic
domain were deleted from wild type CD163. For the tD5 mutant,
the first 5 SRCR domains, the TM domain, and the cytoplasmic
domain were deleted from wild type CD163.
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body. The antiserum was collected by tail bleeding and
stored at -70°C.
Western blot analysis of the purification of the tD4 and
tD5 antigens
Western blot was used to evaluate the protein expres-
sion of tD4 and tD5, as previously described [14]. The
purification samples were subjected to SDS-PAGE with
a 10% gel and electrotransferred to a nitrocellulose
membrane. Nonspecific antibody-binding sites were
blocked with 5% skimmed milk in PBS overnight at 4°C.
The membranes were incubated with a 1:50 dilution of
mouse antiserum to the tD5 protein at 37°C for 1 h and
then washed 4 times with PBST (5 min each). The blot
was probed with a 1:5000 dilution of Odyssey infrared
(IR)-labeled secondary antibody (LI-COR) for 1 h in the
dark at 37°C. Then, the membrane was washed 5 times
with PBST and then twice with PBS. The blot was ana-
lyzed using the Odyssey Infrared Imaging System
(LI-COR).
Indirect ELISA for tD4 and tD5-specific antibody
responses
The tD4 and tD5-specific antibody responses were
determined using an indirect ELISA, with purified
recombinant tD5 protein as the antigen. The 96-well
ELISA plates were coated overnight at 4°C with 15 μgo f
recombinant tD5 protein diluted in 1,997 μLo f5 0m M
sodium carbonate buffer (pH 9.6). The plates were
washed 3 times with PBST wash buffer (0.05% Tween-
20 in PBS) and blocked for 1 h at 37°C with blocking
buffer (3% BSA in PBST). After 3 washes, the serum
samples were diluted by 1:20, 1:40, 1:80, 1:160, 1:320, or
1:640 in blocking buffer, added to each well (100 μL per
well), and incubated for 1 h at 37°C. After 3 washes,
100 μL of HRP-conjugated goat anti-mouse IgG diluted
to 1:500 in blocking buffer was added to each well, and
the plates were incubated at 37°C for 1 h. After 3 washes,
50 μL of tetramethylbenzidine substrate solution was
added to each well for 10 min at room temperature in
the dark. The reaction was stopped by the addition of
50 μL of 1 M HCl to each well. The absorbance was
read at 450 nm by using an ELISA reader.
Results
Gene amplification and construction of expression
plasmids
Using the pcDNA3.1-CD163-D4 and pcDNA3.1-CD163-
D5 plasmids as templates, the CD163 tD4 and CD163
tD5 genes were amplified. The electrophoretic analysis
results of the amplified products showed that the size of
the CD163 tD4 and CD163 tD5 genes were the same as
expected (Figure 2a). The PCR products of the CD163
tD4 and CD163 tD5 genes were digested by Hind III
and Xho I, respectively, and directionally inserted into
the pET-28a(+) plasmid in order to construct the
expression plasmids. The restriction digestion analysis
showed that the pET-28a-tD4 and pET-28a-tD5 expres-
sion plasmids were successfully constructed (Figure 2b).
Protein expression and purification
The levels of protein expression were analyzed by SDS-
PAGE. The optimized conditions for the expression of
the recombinant tD4 and tD5 proteins were induced 4 h
after the addition of 1.0 mmol/L IPTG (Additional file 1:
Fig. S1 and Additional file 2: Fig. S2); the proteins were
highly expressed in the supernatant from the tD4- and
tD5-producing cells that were incubated with a binding
buffer containing the following compounds: b-mercap-
toethanol, urea, Tween 20, glycerol, and SDS, while they
were rarely expressed in the supernatant from the tD4-
and tD5-producing cells that were incubated with bind-
ing buffer without the compounds (Figure 3). The
recombinant tD4 and tD5 proteins were purified from
the induced bacterial cells by using Ni Sepharose 6 Fast
Flow gravity-flow columns (Additional file 3: Fig. S3).
Polyclonal antibody production and western blot analysis
and indirect ELISA
T h ep r o t e i n sw e r eu s e dt oi m m u n i z eB A L B / cm i c e .
After 3 injections, the mice anti-tD4 or anti-tD5 serum
was collected by tail bleeding and stored at -70°C. In
order to evaluate the level of protein expression of tD4
and tD5, western blot was used with the anti-tD5
serum as the antibody. The results showed that the pro-
teins were reactive to the anti-tD5 serum (Figure 4).
The tD4 and tD5-specific antibody responses were
determined using an indirect ELISA, with purified
recombinant tD5 protein as the antigen, and the ELISA
results showed that the titer of both of the antibodies
was 1:160.
Discussion
PRRSV is the causative agent of PRRS and is character-
ized by severe reproductive failure in sows, including
early farrowing of stillborn piglets and late-term abor-
tions, respiratory distress in piglets and growing pigs, as
well as an influenza-like disease in grow-finish swine.
PRRS is one of the most economically important dis-
eases affecting the swine industry worldwide. A highly
pathogenic PRRSV emerged in some swine farms in
China in 2006, and the infection was characterized by
high fever and a high proportion of deaths in pigs of all
ages [4,5]. Although modified live attenuated vaccines
and inactivated vaccines against PRRSV have been avail-
able for more than a decade, the disease remains diffi-
cult to control [15,16].
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cyte/macrophage lineage. CD163 was shown to be a cel-
lular receptor capable of mediating infection of otherwise
PRRSV non-permissive cell lines. A previous report
showed that sialoadhesin and CD163 join forces during
entry of the PRRSV [11]. In addition, SRCR5 is essential
for PRRSV infection [17]. The minor envelope glycopro-
teins GP2a and GP4 of the PRRSV interact with the
receptor CD163 [18]. In order to understand the function
of SRCRs in CD163 and their potential interplay with
other receptors, the prokaryotic expression, purification,
and antibody preparation of the fragment of the extracel-
lular domain of the receptor CD163 were performed.
There was an interesting phenomenon in our experi-
ment: the recombinant tD4 and tD5 proteins were rarely
expressed in the supernatant when the tD4- and tD5-
producing cells used the binding buffer without the fol-
lowing compounds: b-mercaptoethanol, urea, Tween 20,
glycerol, and SDS (Figure 3 lane 1-2 and lane 5-6), while
they were highly expressed in the supernatant when the
tD4- and tD5-producing cells used the binding buffer
with those compounds (Figure 3 lane 3-4 and lane 7-8).
Therefore, it may be beneficial for the release of the tar-
get protein if b-mercaptoethanol, urea, Tween 20, gly-
cerol, and SDS are added to the binding buffer with
which the cells are incubated. In addition, the soluble
protein levels appeared to increase when SDS was added
a l o n et ot h eb i n d i n gb u f f e r .H o w e v e r ,t h ep r o t e i n
expressed in the supernatant was not significantly
changed when the reagents of b-mercaptoethanol, urea,
Tween 20, or glycerol were added alone to the binding
buffer (Additional file 4: Fig. S4). On the contrary, when
4 of the 5 compounds were added to the binding buffer,
the results showed that the proteins were highly
expressed even in the supernatant, when comparing the
binding buffers with the 5 compounds and that with the
5 compounds with the exception of urea or Tween 20 or
glycerol (Additional file 5: Fig. S5). Furthermore, similar
trials were performed with 2 GST recombinant proteins,
and their results were similar with His recombinant pro-
teins (Additional file 6: Fig. S6). Though the expression
levels of the recombinant proteins in the supernatant
were increased in the binding buffer containing the com-
pounds, the purification of the GST-fusion protein failed.
Using the proteins with b-mercaptoethanol, urea,
Tween 20, glycerol, and SDS to immunize the BALB/c
mice, the serum was collected by tail bleeding. The
ELISA results showed that the titer of both antibodies
was 1:160. This indicates that the 5 compounds had no
significant effects on the antibody preparation. Of
course, antigen-presenting may be somewhat affected by
the 5 compounds, according to the hypodermic mass of
the mouse. In summary, these studies lay a foundation
for further study on the function of the potential role of
CD163 in PRRSV entry in macrophages and its potential
interplay with other receptors and provide a new way to
obtain purification of the proteins expressed in inclusion
bodies and the corresponding antibody preparation.
Figure 2 PCR amplification of the tD4 and tD5 genes of CD163 and the restricted enzymatic digestion of pET-28a-tD4 and pET-28a-
tD5. (a) PCR amplification of the tD4 and tD5 genes of CD163: Lane M: DL2000 DNA Markers; lane 1: tD4 PCR product (1742 bp); lane 2: tD5
PCR product (1427 bp); lane 3: negative control PCR product. (b) Restriction enzyme digestion of the pET-28a-tD4 and pET-28a-tD5 plasmids:
Lane M1: l-EcoT14 I digest DNA Markers; lane M2: DL2000 DNA Markers; lane 1: Enzyme digestion of pET-28a-tD4 (5354 bp + 1728 bp); lane 2:
Enzyme digestion of pET-28a-tD5 (5354 bp + 1413 bp).
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In conclusions, the tD4 and tD5 proteins and their antiser-
ums were produced successfully. Western blotting analysis
showed that the tD4 and tD5 proteins were capable of
reacting with tD5 antibodies; the titer of both the tD4 and
tD5 antiserums was 1:160 against the tD5 protein, as
shown by ELISA. These studies provide a new way for the
purification of proteins expressed in inclusion bodies and
the preparation of the corresponding antibodies.
Additional material
Additional file 1: Figure S1: SDS-PAGE analysis of the expression of
tD4 (a) or tD5 (b) products at different times. Lane M: Protein
Markers; lane 1: pET28a non-induced; lane 2: pET28a induced for 4 h (1.0
mmol/L); lane 3: pET-28a-tD4 or pET-28a-tD5 non-induced; lane 4: pET-
28a-tD4 or pET-28a-tD5 induced for 1 h (1.0 mmol/L); lane 5: pET-28a-
tD4 or pET-28a-tD5 induced for 2 h (1.0 mmol/L); lane 6: pET-28a-tD4 or
pET-28a-tD5 induced for 3 h (1.0 mmol/L); lane 7: pET-28a-tD4 or pET-
28a-tD5 induced for 4 h (1.0 mmol/L); lane 8: pET-28a-tD4 or pET-28a-
tD5 induced for 5 h (1.0 mmol/L); lane 9: pET-28a-tD4 or pET-28a-tD5
induced for 6 h (1.0 mmol/L).
Additional file 2: Figure S2: SDS-PAGE analysis of the expression of
tD4 (a) or tD5 (b) products with different concentrations of
isopropyl beta-D-thiogalactopyranoside (IPTG). Lane M: Protein
Markers; lane 1: pET28a non-induced; lane 2: pET28a induced for 5 h (1.0
mmol/L); lane 3: pET-28a-tD4 or pET-28a-tD5 non-induced; lane 4: pET-
28a-tD4 or pET-28a-tD5 induced for 5 h (0.2 mmol/L); lane 5: pET-28a-
tD4 or pET-28a-tD5 induced for 5 h (0.4 mmol/L); lane 6: pET-28a-tD4 or
pET-28a-tD5 induced for 5 h (0.6 mmol/L); lane 7: pET-28a-tD4 or pET-
28a-tD5 induced for 5 h (0.8 mmol/L); lane 8: pET-28a-tD4 or pET-28a-
tD5 induced for 5 h (1.0 mmol/L); lane 9: pET-28a-tD4 or pET-28a-tD5
induced for 5 h (1.2 mmol/L).
Additional files 3: Figure S3: SDS-PAGE analysis of samples taken
during the purification of tD4 (a) or tD5 (b) protein. Lane M: Protein
Markers; lane 1: Supernatant after ultrasonic disruption; lane 2:
Precipitation after ultrasonic disruption; lane 3: Collected flow-though
during loading of tD4 or tD5 protein; lanes 4-6: Collected flow-though
from washing the gravity-flow columns with binding buffer; lanes 7-8:
Collected flow-though from washing the gravity-flow columns with
elution buffer.
Additional file 4: Figure S4: SDS-PAGE analysis of supernatant or
inclusion bodies (one compound was added alone to binding
buffer). Lane M: Protein Markers; Supernatant (lane 1) or Precipitation
(lane 2) after ultrasonic disruption of the tD5-producing cells that used
binding buffer without the compounds; Supernatant (lane 3) or
Precipitation (lane 4) after ultrasonic disruption of the tD5-producing
cells that used binding buffer only with SDS; Supernatant (lane 5) or
Precipitation (lane 6) after ultrasonic disruption of the tD5-producing
cells that used binding buffer only with glycerol; Supernatant (lane 7) or
Precipitation (lane 8) after ultrasonic disruption of the tD5-producing
cells that used binding buffer only with b-mercaptoethanol; Supernatant
(lane 9) or Precipitation (lane 10) after ultrasonic disruption of the tD5-
producing cells that used binding buffer only with Tween 20;
Supernatant (lane 11) or Precipitation (lane 12) after ultrasonic disruption
of the tD5-producing cells that used binding buffer only with urea;
Supernatant (lane 13) or Precipitation (lane 14) after ultrasonic disruption
of the tD5-producing cells that used binding buffer containing the five
compounds: b-mercaptoethanol, urea, Tween 20, glycerol, and SDS.
Additional file 5: Figure S5: SDS-PAGE analysis of supernatant or
inclusion bodies (four compounds were added to binding buffer).
Lane M: Protein Markers; Supernatant (lane 1) or Precipitation (lane 2)
after ultrasonic disruption of the tD5-producing cells that used binding
buffer with the five compounds: b-mercaptoethanol, urea, Tween 20,
glycerol, and SDS; Supernatant (lane 3) or Precipitation (lane 4) after
ultrasonic disruption of the tD5-producing cells that used binding buffer
with the 5 compounds with the exception of urea; Supernatant (lane 5)
or Precipitation (lane 6) after ultrasonic disruption of the tD5-producing
cells that used binding buffer with the 5 compounds with the exception
of Tween 20; Supernatant (lane 7) or Precipitation (lane 8) after ultrasonic
disruption of the tD5-producing cells that used binding buffer with the 5
compounds with the exception of b-mercaptoethanol; Supernatant (lane
Figure 4 Western blot analysis of tD4 or tD5 protein.L a n eM :
Protein Markers; lane 1: tD4 protein; lane 2: tD5 protein.
Figure 3 SDS-PAGE analysis of supernatant or inclusion bodies
after ultrasonic disruption. Lane M: Protein Markers; lane 1:
Supernatant after ultrasonic disruption of the tD4-producing cells
that used binding buffer without the compounds; lane 2:
Precipitation after ultrasonic disruption of the tD4-producing cells
that used binding buffer without the compounds; lane 3:
Supernatant after ultrasonic disruption of the tD4-producing cells
that used binding buffer containing the compounds b-
mercaptoethanol, urea, Tween 20, glycerol, and SDS; lane 4:
Precipitation after ultrasonic disruption of the tD4-producing cells
that used binding buffer with the compounds; lane 5: Supernatant
after ultrasonic disruption of the tD5-producing cells that used
binding buffer without the compounds; lane 6: Precipitation after
ultrasonic disruption of the tD5-producing cells that used binding
buffer without the compounds; lane 7: Supernatant after ultrasonic
disruption of the tD5-producing cells that used binding buffer with
the compounds; lane 8: Precipitation after ultrasonic disruption of
the tD5-producing cells that used binding buffer with the
compounds.
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producing cells that used binding buffer with the 5 compounds with the
exception of glycerol; Supernatant (lane 11) or Precipitation (lane 12)
after ultrasonic disruption of the tD5-producing cells that used binding
buffer with the 5 compounds with the exception of SDS; Supernatant
(lane 13) or Precipitation (lane 14) after ultrasonic disruption of the tD5-
producing cells that used binding buffer without the compounds.
Additional file 6: Figure S6: SDS-PAGE analysis of supernatant or
inclusion bodies after ultrasonic disruption of the cells from the
production of GST recombinant fusion protein. Lane M: Protein
Markers; lane 1: Supernatant after ultrasonic disruption of the GST-A-
producing cells that used the binding buffer without the compounds;
lane 2: Precipitation after ultrasonic disruption of the GST-A-producing
cells that used the binding buffer without the compounds; lane 3:
Supernatant after ultrasonic disruption of the cells from the production
of GST-A using binding buffer with the following compounds: b-
mercaptoethanol, urea, Tween 20, glycerol, and SDS; lane 4: Precipitation
after ultrasonic disruption of the GST-A-producing cells that used binding
buffer with the compounds; lane 5: Supernatant after ultrasonic
disruption of the GST-B-producing cells that used the binding buffer
without the compounds; lane 6: Precipitation after ultrasonic disruption
of the GST-B-producing cells that used the binding buffer without the
compounds; lane 7: Supernatant after ultrasonic disruption of the GST-B-
producing cells that used the binding buffer with the compounds; lane
8: Precipitation after ultrasonic disruption of the GST-B-producing cells
that used the binding buffer with the compounds.
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